Claims for Patent: 8,003,697

Summary for Patent: 8,003,697

Title:	Disodium salts, monohydrates, and ethanol solvates for delivering active agents
Abstract:	The inventors have discovered that the disodium salt of certain delivery agents has surprisingly greater efficacy for delivering active agents than the corresponding monosodium salt. Furthermore, the inventors have discovered that the disodium salts of these delivery agents form solvates with ethanol and hydrates with water. The delivery agents have the formula ##STR00001## wherein R.sup.1, R.sup.2, R.sup.3, and R.sup.4 are independently hydrogen, halogen, C.sub.1-C.sub.4 alkyl, or C.sub.1-C.sub.4 alkoxy; and R.sup.5 is a substituted or unsubstituted C.sub.2-C.sub.16 alkylene, substituted or unsubstituted C.sub.2-C.sub.16 alkenylene, substituted or unsubstituted C.sub.1-C.sub.12 alkyl(arylene), or substituted or unsubstituted aryl(C.sub.1-C.sub.12 alkylene). The hydrates and solvates of present invention also have surprisingly greater efficacy for delivering active agents, such as heparin and calcitonin, than their corresponding monosodium salts and free acids. The present invention provides an alcohol solvate, such as ethanol solvate, of a disodium salt of a delivery agent of the formula above. The invention also provides a hydrate of a disodium salt of a delivery agent of the formula above. Preferred delivery agents include, but are not limited to, N-(5-chlorosalicyloyl)-8-aminocaprylic acid (5-CNAC), N-(10-[2-hydroxybenzoyl]amino)decanoic acid (SNAD), and sodium N-(8-[2-hydroxybenzoyl]amino)caprylate (SNAC). The invention also provides methods of preparing the disodium salt, ethanol solvate, and hydrate and compositions containing the disodium salt, ethanol solvate, and/or hydrate.
Inventor(s):	Bay; William Elliot (Ridgefield, CT), Agarwal; Rajesh K. (San Diego, CA), Chaudhary; Kiran (West Nyack, NY), Goldberg; Michael M. (Englewood, NJ), Corvino; JoAnne P. (West Harrison, NY), Majura; Shingai (Brewster, NY), Azria; Moise (Basel, CH), Ault; Joseph (Blairstown, NJ), Bateman; Simon D. (Randolph, NJ), Patel; Subash (Somerville, NJ), Sikora; Joseph (Succasunna, NJ), Yang; Rebecca F. (Randolph, NJ), Zielinski; Joseph (Florham Park, NJ)
Assignee:	Emisphere Technologies, Inc. (Cedar Knolls, NJ) Novartis AG (Basel, CH)
Application Number:	12/642,508
Patent Claims:	1. A solid pharmaceutical composition comprising from about 50% to about 100% by weight of the disodium salt of N-(5-chlorosalicyloyl)-8-aminocaprylic acid, based upon 100% total weight of N-(5-chlorosalicyloyl)-8-aminocaprylic acid and salts thereof in the composition, and (b) a biologically active agent selected from human growth hormone, parathyroid hormone, and a biologically active fragment of parathyroid hormone. 2. The solid pharmaceutical composition of claim 1, wherein the biologically active agent is human growth hormone. 3. The solid pharmaceutical composition of claim 1, wherein the biologically active agent is parathyroid hormone or a biologically active fragment thereof. 4. The solid pharmaceutical composition of claim 1, wherein the composition comprises from about 90% to about 100% by weight of the disodium salt of N-(5-chlorosalicyloyl)-8-aminocaprylic acid based upon 100% total weight of N-(5-chlorosalicyloyl)-8-aminocaprylic acid and salts thereof in the composition, and the biologically active agent is human growth hormone. 5. The solid pharmaceutical composition of claim 1, wherein the composition comprises from about 90% to about 100% by weight of the disodium salt of N-(5-chlorosalicyloyl)-8-aminocaprylic acid based upon 100% total weight of N-(5-chlorosalicyloyl)-8-aminocaprylic acid and salts thereof in the composition, and the biologically active agent is parathyroid hormone or a biologically active fragment thereof. 6. The solid pharmaceutical composition of claim 4, wherein the composition comprises from about 96% to 100% by weight of the disodium salt of N-(5-chlorosalicyloyl)-8-aminocaprylic acid, based upon 100% total weight of N-(5-chlorosalicyloyl)-8-aminocaprylic acid and salts thereof in the composition. 7. The solid pharmaceutical composition of claim 5, wherein the composition comprises at least from about 96% to 100% by weight of the disodium salt of N-(5-chlorosalicyloyl)-8-aminocaprylic acid, based upon 100% total weight of N-(5-chlorosalicyloyl)-8-aminocaprylic acid and salts thereof in the composition. 8. A solid pharmaceutical composition comprising at least from about 96% to 100% by weight of the disodium salt of N-(5-chlorosalicyloyl)-8-aminocaprylic acid, based upon 100% total weight of N-(5-chlorosalicyloyl)-8-aminocaprylic acid and salts thereof in the composition, and (b) a biologically active agent selected from calcitonin, human growth hormone, parathyroid hormone, and a biologically active fragment of parathyroid hormone.

Details for Patent 8,003,697

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Nps Pharmaceuticals, Inc.	NATPARA	parathyroid hormone	For Injection	125511	01/23/2015		2019-04-05